Twist Bioscience (TWST)
NASDAQ:TWST
Want to see TWST full AI Analyst Report?
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:62Neutral
Price Target:
$52.00
▼(-13.06% Downside)
Action:Reiterated
Date:05/09/26
The score is driven by improving fundamentals and a supportive balance sheet but still-material cash burn and losses. Technicals are generally favorable with a strong longer-term uptrend and positive MACD, while valuation is constrained by negative earnings and no dividend. The latest earnings call adds support via raised revenue guidance and a defined path to adjusted-EBITDA breakeven, partially offset by cash decline and litigation-related costs.
Positive Factors
Consistent revenue growth
Thirteen consecutive quarters of sequential revenue growth and 19% YoY expansion show durable commercial traction across customer segments. Sustained top-line scaling indicates expanding market adoption of Twist’s DNA synthesis platform, aiding capacity planning and long-term revenue visibility.
Negative Factors
Negative operating and free cash flow
Persistent negative OCF and deeply negative FCF imply ongoing cash burn during scale-up, pressuring liquidity and forcing reliance on financing or equity. Even with a quarter‑end cash balance, sustained cash outflows constrain reinvestment or require tradeoffs in timing of break‑even targets.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Thirteen consecutive quarters of sequential revenue growth and 19% YoY expansion show durable commercial traction across customer segments. Sustained top-line scaling indicates expanding market adoption of Twist’s DNA synthesis platform, aiding capacity planning and long-term revenue visibility.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.77B
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth17.77%
EPS Growth59.40%
CountryUS
Employees923
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.32
Shares Outstanding62,271,313
10 Day Avg. Volume1,454,017
30 Day Avg. Volume1,516,139
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue9.15
Enterprise Value/Gross Profit17.56
Enterprise Value/Ebitda-64.32
Forecast
1Y Price Target
$63.43Price Target Upside6.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.05
Revenue Forecast (FY)$446.61M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic D...
How the Company Makes Money
Twist Bioscience makes money primarily by selling synthetic DNA products and related services to life-science and industrial customers. Key revenue streams include: (1) Sales of synthetic DNA products, such as genes/gene fragments and clonal genes...
Twist Bioscience Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.Positive Updates
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Negative Updates
Adjusted EBITDA Still Negative
Adjusted EBITDA loss of approximately $13.3M in Q2, although improved ~$1.5M year-over-year; company remains on a path to breakeven but is not yet profitable on an adjusted EBITDA basis.
Read all updates
Q2-2026 Updates
Positive
Negative
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Read all positive updates
Company Guidance
Twist guided fiscal 2026 revenue of $442–447 million (growth ~17–19%) and Q3 revenue of $114–115 million (≈19% YoY at the midpoint), said NGS will drive H2 sequential growth and return to ~20% growth by Q4, and reiterated a target of adjusted‑EBITDA breakeven in Q4 FY2026. They expect full‑year gross margin of ~52%+ (Q2 was 51.6%), cited a 75–80% average incremental gross‑margin drop‑through on new revenue, and plan approximately $6 million of sequential OpEx improvement in Q4 from cost actions; Q2 adjusted EBITDA was a loss of ~$13.3 million (an improvement of ~$1.5M YoY). Cash was $171.7 million at quarter end (versus $197.9M at 12/31/25); Q2 used $17.6M in operating cash, spent $7.9M in CapEx and $5.0M on the Invenra license, and recorded $7.2M of litigation settlement costs as part of a ~$17.1M class‑action resolution expected to be largely insurance‑covered.Twist Bioscience Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
74
Positive
Cash Flow
43
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 409.48M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 213.23M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -58.23M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -81.28M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 676.21M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 171.67M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 95.84M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 221.12M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 455.09M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -95.14M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -55.59M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -44.44M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 11.84M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Positive
59.81
Price Trends
53.04
Positive
48.61
Positive
39.08
Positive
Market Momentum
0.18
Negative
60.12
Neutral
79.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Positive. The current price of 59.81 is above the 20-day moving average (MA) of 56.23, above the 50-day MA of 53.04, and above the 200-day MA of 39.08, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 79.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.12B | 79.03 | -2.61% | ― | 19.17% | -111.99% | |
62 Neutral | $3.77B | -16.65 | -17.46% | ― | 17.77% | 59.40% | |
59 Neutral | $2.88B | -5.63 | -16.42% | ― | 19.44% | 82.94% | |
57 Neutral | $1.20B | -2.80 | -11.82% | ― | 10.95% | -26.52% | |
56 Neutral | $485.93M | -4.94 | -6.70% | ― | 9.54% | -79.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $360.79M | -3.09 | -109.09% | ― | -0.28% | -286.80% |
* Healthcare Sector Average
TWST
Twist Bioscience
60.57
32.31
114.33%
MYGN
Myriad Genetics
3.82
-0.09
-2.30%
NEO
NeoGenomics
9.23
1.82
24.56%
CDNA
CareDx
21.63
4.68
27.61%
FLGT
Fulgent Genetics
17.11
-3.20
-15.76%
GRAL
GRAIL Inc
67.19
24.85
58.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.